Long-circulating Targeted Nanoparticles for Cancer Therapy
Journal:
Current Nanoscience
Volume:
6
Page:
347-354
Author(s):
Yang Liu, Jin Sun, Jihong Han and Zhonggui He
Past, Present and Future of Targeted Therapy in Solid Tumors
Journal:
Current Cancer Drug Targets
Volume:
10
Page:
433-461
Author(s):
A. Palazzo, R. Iacovelli and E. Cortesi
Tyrosine Kinase Inhibitors
Journal:
Current Cancer Drug Targets
Volume:
10
Page:
462-483
Author(s):
C. Natoli, B. Perrucci, F. Perrotti, L. Falchi and S. Iacobelli
Circulating Tumor Cells in Cancer Therapy: Are we off Target?
Journal:
Current Cancer Drug Targets
Volume:
10
Page:
509-518
Author(s):
C. Raimondi, G. Naso, A. Gradilone, W. Gianni, E. Cortesi and P. Gazzaniga
Personalized Medicine in Oncology: A Personal View with Myths and Facts
Journal:
Current Clinical Pharmacology
Volume:
5
Page:
141-147
Author(s):
Jos H. Beijnen and Jan H.M. Schellens
Monoclonal Antibody Therapy in Haematological Malignancies
Journal:
Current Clinical Pharmacology
Volume:
5
Page:
148-159
Author(s):
Martine E.D. Chamuleau, Arjan A. van de Loosdrecht and Peter C. Huijgens
Monoclonal Antibodies in Solid Tumours
Journal:
Current Clinical Pharmacology
Volume:
5
Page:
160-165
Author(s):
Ben Markman and Josep Tabernero
Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives
Journal:
Current Clinical Pharmacology
Volume:
5
Page:
166-177
Author(s):
Otto Metzger-Filho, Camilo Moulin and Ahmad Awada
Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Journal:
Current Clinical Pharmacology
Volume:
5
Page:
186-191
Author(s):
Suzanne Leijen, Jos H. Beijnen and Jan H.M. Schellens
Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Journal:
Current Clinical Pharmacology
Volume:
5
Page:
209-217
Author(s):
Ken-ichi Fujita and Alex Sparreboom